Qualitative and quantitative methods in post-chemoradiation PET for head and neck cancer.
Chemoradiotherapy
Fluorodeoxyglucose F18
Head and Neck Neoplasms
/ diagnostic imaging
Humans
Neoplasm Recurrence, Local
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Positron-Emission Tomography
/ methods
Radiopharmaceuticals
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
pubmed:
14
4
2022
medline:
18
5
2022
entrez:
13
4
2022
Statut:
ppublish
Résumé
The aim of this study was to determine whether quantitative methods could aid in the evaluation of post-treatment head and neck scans, particularly taking human papillomavirus status into account. Clinical readings of positron emission tomography/computed tomography scans as well as standardized uptake value (SUV)max (and other metrics) of nodes visible on PET conducted on a total of 172 patients with head and neck squamous cell cancer were examined. Locoregional recurrence at 2 years was assessed. In total 88 of these patients had close enough follow-up to determine whether individual nodes were positive or negative, and 233 nodes on these patients were compared to surgical pathology notes or follow-up (if no path was available). General negative predictive value (NPV) of complete response was 93% and an equivocal response was 89%; focusing on nodal recurrence, NPV was found to be 97% and positive predictive value (PPV) 46% if equivocal reads were treated as negative and NPV 98% and PPV 16% if equivocal reads were treated as positive. Using SUVmax of the hottest node with a cutoff of 3.4 gave NPV 97% and PPV 26%; a direct re-read (using 2 observers) gave NPV 98% and PPV 32% if equivocal reads were treated as negative, and NPV 99% and PPV 18% if equivocal reads were treated as positive. Using other first-order radiomics data such as SD and skewness did not improve this. Quantitative data such as SUVmax does not show additional value over qualitative evaluation of response to chemoradiation in head and neck tumors.
Identifiants
pubmed: 35414636
doi: 10.1097/MNM.0000000000001558
pii: 00006231-202206000-00013
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
710-716Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011; 38:2083–2095.
Fleming JC, Woo J, Moutasim K, Mellone M, Frampton SJ, Mead A, et al. HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. Br J Cancer 2019; 120:356–367.
Clark J, Jeffery CC, Zhang H, Cooper T, O’Connell DA, Harris J, et al. Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 2015; 44:37.
Schouten CS, Hakim S, Boellaard R, Bloemena E, Doornaert PA, Witte BI, et al. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. Head Neck 2016; 38:529–535.
Joo YH, Yoo IeR, Lee YS, Cho KJ, Park JO, Nam IC, et al. Association between the standardized uptake value and high-risk HPV in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2014; 134:1062–1070.
Tahari AK, Alluri KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. Clin Nucl Med 2014; 39:225–231.
Sharma SJ, Wittekindt C, Knuth J, Steiner D, Wuerdemann N, Laur M, et al. Intraindividual homogeneity of 18F-FDG PET/CT parameters in HPV-positive OPSCC. Oral Oncol 2017; 73:166–171.
Su W, Miles BA, Posner M, Som P, Kostakoglu L, Gupta V, Bakst RL. Surveillance imaging in HPV-related oropharyngeal cancer. Anticancer Res 2018; 38:1525–1529.
Helsen N, Van den Wyngaert T, Carp L, Stroobants S. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. Eur J Nucl Med Mol Imaging 2018; 45:1063–1071.
Rulach R, Zhou S, Hendry F, Stobo D, James A, Dempsey MF, et al. 12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers. Oral Oncol 2019; 97:76–81.
Wotman M, Ghaly M, Massaro L, Tham T, Seetharamu N, Kamdar D, et al. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: an institutional experience. Am J Otolaryngol 2019; 40:684–690.
Moan JM, Amdal CD, Malinen E, Svestad JG, Bogsrud TV, Dale E. The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status. Radiother Oncol 2019; 140:54–61.
Gouw ZAR, La Fontaine MD, van Kranen S, van de Kamer JB, Vogel WV, van Werkhoven E, et al. The prognostic value of baseline 18F-FDG PET/CT in human papillomavirus-positive versus human papillomavirus-negative patients with oropharyngeal cancer. Clin Nucl Med 2019; 44:e323–e328.
Banks KP, Peacock JG, Gusman M, Clemenshaw MN. It’s about quality, not quantity: qualitative FDG PET/CT criteria for therapy response assessment in clinical practice. AJR Am J Roentgenol 2020; 215:313–324.
Peacock JG, Christensen CT, Banks KP. RESISTing the need to quantify: putting qualitative FDG-PET/CT tumor response assessment criteria into daily practice. AJNR Am J Neuroradiol 2019; 40:1978–1986.
Wang K, Wong TZ, Amdur RJ, Mendenhall WM, Sheets NC, Green R, et al. Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: secondary analysis of a phase 2 trial. Oral Oncol 2018; 78:108–113.
National Comprehensive Cancer Network. NCCN Guidelines: Head and Neck Cancers, Version 1. 2022. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . [Accessed 5 March 2022].
Liu HY, Milne R, Lock G, Panizza BJ, Bernard A, Foote M, et al. Utility of a repeat PET/CT scan in HPV-associated oropharyngeal cancer following incomplete nodal response from (chemo)radiotherapy. Oral Oncol 2019; 88:153–159.
Corpman DW, Masroor F, Carpenter DM, Nayak S, Gurushanthaiah D, Wang KH. Posttreatment surveillance PET/CT for HPV-associated oropharyngeal cancer. Head Neck 2019; 41:456–462.
Ng SP, Johnson JM, Gunn GB, Rosenthal DI, Skinner HD, Phan J, et al. Significance of negative posttreatment 18-FDG PET/CT imaging in patients with p16/HPV-positive oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2018; 102:1029–1035.
Baxter M, Chan JY, Mydlarz WK, Labruzzo SV, Kiess A, Ha PK, et al. Retropharyngeal lymph node involvement in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Laryngoscope 2015; 125:2503–2508.
Mena E, Taghipour M, Sheikhbahaei S, Jha AK, Rahmim A, Solnes L, Subramaniam RM. Value of intratumoral metabolic heterogeneity and quantitative 18F-FDG PET/CT parameters to predict prognosis in patients with HPV-positive primary oropharyngeal squamous cell carcinoma. Clin Nucl Med 2017; 42:e227–e234.
Floberg JM, DeWees TA, Chin RI, Garsa AA, Dehdashti F, Nussenbaum B, et al. Pretreatment metabolic tumor volume as a prognostic factor in HPV-associated oropharyngeal cancer in the context of AJCC 8 th edition staging. Head Neck 2018; 40:2280–2287.
Aramburu Núñez D, Lopez Medina A, Mera Iglesias M, Salvador Gomez F, Dave A, Hatzoglou V, et al. Multimodality functional imaging using DW-MRI and 18F-FDG-PET/CT during radiation therapy for human papillomavirus negative head and neck squamous cell carcinoma: Meixoeiro Hospital of Vigo Experience. World J Radiol 2017; 9:17–26.